High-Throughput Dynamic Light Scattering
Wyatt Technology is the recognized leader in instrumentation for biophysical screening and characterization of peptides, proteins, polymers, and nanoparticles based on multi-angle and dynamic light scattering. Wyatt pioneered SEC -MALS for absolute molar mass measurements in solution and the dynamic light scattering plate reader, used by all leading biopharmaceutical developers.
Products and Services
The DynaPro PRII DLS plate reader measures size and aggregation of biopharmaceuticals in standard 96, 384, or 1536 well plates. It can rapidly screen proteins, liposomes, viruses, or VL Ps in dozens of formulations, or test developability in early stages of development including stability assessments and viscosity of high-concentration mAbs.
Wyatt Technology Corporation
6330 Hollister Avenue, Santa Barbara, CA 93117
info@wyatt.com
tel. 805.681.9009
fax. 805.681.0123
The Future of Cleanroom Construction: How Hybrid Solutions are Changing the Game
May 14th 2025Imagine a world where cleanroom facilities—essential for pharmaceutical manufacturing, biotechnology, and high-tech industries—are built with unparalleled speed, precision, and efficiency. That world is here, thanks to the hybrid construction approach. By blending traditional stick-built methods with modular and prefabricated solutions, companies are overcoming the limitations of conventional construction while ensuring compliance with stringent industry regulations. In this interview, we explore how hybrid cleanroom construction is transforming the industry, offering faster project timelines, improved quality control, and significant cost advantages. Join us as we delve into this game-changing approach with industry experts who are leading the charge in revolutionizing cleanroom infrastructure.
Mastering Antibody-Drug Conjugates
December 19th 2024In this episode, we explore BIOVECTRA’s capabilities in antibody-drug conjugate (ADC) manufacturing, from complex conjugation chemistry to synthesis of highly potent payloads. We’ll also showcase how BIOVECTRA’s extensive experience in complex chemistries and specialized small molecule manufacturing gives them a unique perspective, strengthening their approach to ADC production and ensuring clients receive custom solutions across all project stages.
Kyron.bio Raises €5.5M to Advance Precision Glycan Engineering for Safer Antibody Therapeutics
May 28th 2025Funding will support the company’s efforts to refine its proprietary glycan-engineering platform, expand its scientific and operational team, and advance preclinical studies of its engineered biologics.